Opinion|Videos|November 27, 2025
Barriers to Adoption of SC Therapies
Panelists discuss how overcoming logistical and perceptual barriers will drive wider adoption of SC therapies in NSCLC.
Advertisement
Episodes in this series
Panelists discuss how barriers such as provider hesitancy, reimbursement concerns, and logistical complexities slow the adoption of subcutaneous (SC) therapies. They propose strategies including education, workflow redesign, and advocacy to increase confidence in SC delivery. The discussion emphasizes that as data accumulate and experience grows, institutional and cultural shifts will further integrate SC therapy
Advertisement
Related to this article
Experts at CHEST 2026 urge pulmonologists to keep lung cancer in mind for younger patients who never smoked, to order screening and biomarker testing themselves, and to advocate for patients' access to care.
Phentolamine 0.75% (Ryzumvi) won FDA approval for presbyopia based on the phase 3 VEGA-2 and VEGA-3 trials.
Satralizumab, a first-in-class IL-6 receptor inhibitor, was approved for adults with thyroid eye disease based on the phase 3 SatraGO program.
A higher PNR is associated with lower odds of MASLD and advanced liver fibrosis, but further studies are needed to validate findings.
Speakers at CHEST 2026 walked through the first CHEST guideline for non-CF adult bronchiectasis, including which preventive therapy to start first.
SaTScan detects an acute HCV outbreak cluster in California, showing the potential of automated surveillance, though real-time testing is needed.
Genetic analysis finds 125 loci shared by insomnia and CRP, with Mendelian randomization favoring an effect from insomnia liability to inflammation.
Proinflammatory diets were tied to higher mortality in MASLD and MetALD, whereas antioxidant-rich diets tracked with better survival.
Advertisement
Advertisement
Trending on AJMC
1
FDA Approves Ryzumvi for Presbyopia, Expanding its Label
2
New CHEST Guidelines Offer a Road Map for Bronchiectasis
3
CHEST Highlights Practice-Changing COPD Therapy and Strategies
4
CHEST Investigations Explore COPD Guideline Adherence, Adding Ensifentrine, and Use of AI in Education
5